CSF1R and epilepsy: In addition to validating CRAFT as a predictive framework for drug target discovery, these results identify Csf1R inhibition as a potential novel therapeutic strategy in epilepsy and provide further evidence to support the role of innate immunity in the occurrence and maintenance of seizures in acquired epilepsy14,43.